Global Bi-Specific Antibodies Therapy Market 2022 by Company, Regions, Type and Application, Forecast to 2028

  • receipt Report ID : 265352
  • calendar_today Published On: Jan, 2022
  • file_copy Pages: 156
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The Bi-Specific Antibodies Therapy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest study, due to COVID-19 pandemic, the global Bi-Specific Antibodies Therapy market size is estimated to be worth US$ 3360.6 million in 2021 and is forecast to a readjusted size of USD 16260 million by 2028 with a CAGR of 25.3% during review period. Cancer accounting for % of the Bi-Specific Antibodies Therapy global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Fragment-Based Antibodies segment is altered to a % CAGR between 2022 and 2028.

Global key companies of Bi-Specific Antibodies Therapy include Roche, Amgen, Sanofi, Pfizer, and Johnson & Johnson, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

Bi-Specific Antibodies Therapy market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Fragment-Based Antibodies

IgG-Based Antibodies

Market segment by Application, can be divided into

Cancer

Haemophilia

Other Non-Cancer Diseases

Market segment by players, this report covers

Roche

Amgen

Sanofi

Pfizer

Johnson & Johnson

AstraZeneca

AbbVie

Lindis Biotech

MacroGenics, Inc

Genmab

Alphamab Co. Ltd

Akeso, Inc.

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:

Chapter 1, to describe Bi-Specific Antibodies Therapy product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Bi-Specific Antibodies Therapy, with revenue, gross margin and global market share of Bi-Specific Antibodies Therapy from 2019 to 2022.

Chapter 3, the Bi-Specific Antibodies Therapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Bi-Specific Antibodies Therapy market forecast, by regions, type and application, with revenue, from 2023 to 2028.

Chapter 11 and 12, to describe Bi-Specific Antibodies Therapy research findings and conclusion, appendix and data source.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Bi-Specific Antibodies Therapy

1.2 Classification of Bi-Specific Antibodies Therapy by Type

1.2.1 Overview: Global Bi-Specific Antibodies Therapy Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global Bi-Specific Antibodies Therapy Revenue Market Share by Type in 2021

1.2.3 Fragment-Based Antibodies

1.2.4 IgG-Based Antibodies

1.3 Global Bi-Specific Antibodies Therapy Market by Application

1.3.1 Overview: Global Bi-Specific Antibodies Therapy Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Cancer

1.3.3 Haemophilia

1.3.4 Other Non-Cancer Diseases

1.4 Global Bi-Specific Antibodies Therapy Market Size & Forecast

1.5 Global Bi-Specific Antibodies Therapy Market Size and Forecast by Region

1.5.1 Global Bi-Specific Antibodies Therapy Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Bi-Specific Antibodies Therapy Market Size by Region, (2017-2022)

1.5.3 North America Bi-Specific Antibodies Therapy Market Size and Prospect (2017-2028)

1.5.4 Europe Bi-Specific Antibodies Therapy Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Bi-Specific Antibodies Therapy Market Size and Prospect (2017-2028)

1.5.6 South America Bi-Specific Antibodies Therapy Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Bi-Specific Antibodies Therapy Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Bi-Specific Antibodies Therapy Market Drivers

1.6.2 Bi-Specific Antibodies Therapy Market Restraints

1.6.3 Bi-Specific Antibodies Therapy Trends Analysis

2 Company Profiles

2.1 Roche

2.1.1 Roche Details

2.1.2 Roche Major Business

2.1.3 Roche Bi-Specific Antibodies Therapy Product and Solutions

2.1.4 Roche Bi-Specific Antibodies Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 Roche Recent Developments and Future Plans

2.2 Amgen

2.2.1 Amgen Details

2.2.2 Amgen Major Business

2.2.3 Amgen Bi-Specific Antibodies Therapy Product and Solutions

2.2.4 Amgen Bi-Specific Antibodies Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Amgen Recent Developments and Future Plans

2.3 Sanofi

2.3.1 Sanofi Details

2.3.2 Sanofi Major Business

2.3.3 Sanofi Bi-Specific Antibodies Therapy Product and Solutions

2.3.4 Sanofi Bi-Specific Antibodies Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 Sanofi Recent Developments and Future Plans

2.4 Pfizer

2.4.1 Pfizer Details

2.4.2 Pfizer Major Business

2.4.3 Pfizer Bi-Specific Antibodies Therapy Product and Solutions

2.4.4 Pfizer Bi-Specific Antibodies Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 Pfizer Recent Developments and Future Plans

2.5 Johnson & Johnson

2.5.1 Johnson & Johnson Details

2.5.2 Johnson & Johnson Major Business

2.5.3 Johnson & Johnson Bi-Specific Antibodies Therapy Product and Solutions

2.5.4 Johnson & Johnson Bi-Specific Antibodies Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 Johnson & Johnson Recent Developments and Future Plans

2.6 AstraZeneca

2.6.1 AstraZeneca Details

2.6.2 AstraZeneca Major Business

2.6.3 AstraZeneca Bi-Specific Antibodies Therapy Product and Solutions

2.6.4 AstraZeneca Bi-Specific Antibodies Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 AstraZeneca Recent Developments and Future Plans

2.7 AbbVie

2.7.1 AbbVie Details

2.7.2 AbbVie Major Business

2.7.3 AbbVie Bi-Specific Antibodies Therapy Product and Solutions

2.7.4 AbbVie Bi-Specific Antibodies Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7.5 AbbVie Recent Developments and Future Plans

2.8 Lindis Biotech

2.8.1 Lindis Biotech Details

2.8.2 Lindis Biotech Major Business

2.8.3 Lindis Biotech Bi-Specific Antibodies Therapy Product and Solutions

2.8.4 Lindis Biotech Bi-Specific Antibodies Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.8.5 Lindis Biotech Recent Developments and Future Plans

2.9 MacroGenics, Inc

2.9.1 MacroGenics, Inc Details

2.9.2 MacroGenics, Inc Major Business

2.9.3 MacroGenics, Inc Bi-Specific Antibodies Therapy Product and Solutions

2.9.4 MacroGenics, Inc Bi-Specific Antibodies Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9.5 MacroGenics, Inc Recent Developments and Future Plans

2.10 Genmab

2.10.1 Genmab Details

2.10.2 Genmab Major Business

2.10.3 Genmab Bi-Specific Antibodies Therapy Product and Solutions

2.10.4 Genmab Bi-Specific Antibodies Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10.5 Genmab Recent Developments and Future Plans

2.11 Alphamab Co. Ltd

2.11.1 Alphamab Co. Ltd Details

2.11.2 Alphamab Co. Ltd Major Business

2.11.3 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Product and Solutions

2.11.4 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.11.5 Alphamab Co. Ltd Recent Developments and Future Plans

2.12 Akeso, Inc.

2.12.1 Akeso, Inc. Details

2.12.2 Akeso, Inc. Major Business

2.12.3 Akeso, Inc. Bi-Specific Antibodies Therapy Product and Solutions

2.12.4 Akeso, Inc. Bi-Specific Antibodies Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.12.5 Akeso, Inc. Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Bi-Specific Antibodies Therapy Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Bi-Specific Antibodies Therapy Players Market Share in 2021

3.2.2 Top 10 Bi-Specific Antibodies Therapy Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Bi-Specific Antibodies Therapy Players Head Office, Products and Services Provided

3.4 Bi-Specific Antibodies Therapy Mergers & Acquisitions

3.5 Bi-Specific Antibodies Therapy New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Bi-Specific Antibodies Therapy Revenue and Market Share by Type (2017-2022)

4.2 Global Bi-Specific Antibodies Therapy Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5.1 Global Bi-Specific Antibodies Therapy Revenue Market Share by Application (2017-2022)

5.2 Global Bi-Specific Antibodies Therapy Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6.1 North America Bi-Specific Antibodies Therapy Revenue by Type (2017-2028)

6.2 North America Bi-Specific Antibodies Therapy Revenue by Application (2017-2028)

6.3 North America Bi-Specific Antibodies Therapy Market Size by Country

6.3.1 North America Bi-Specific Antibodies Therapy Revenue by Country (2017-2028)

6.3.2 United States Bi-Specific Antibodies Therapy Market Size and Forecast (2017-2028)

6.3.3 Canada Bi-Specific Antibodies Therapy Market Size and Forecast (2017-2028)

6.3.4 Mexico Bi-Specific Antibodies Therapy Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7.1 Europe Bi-Specific Antibodies Therapy Revenue by Type (2017-2028)

7.2 Europe Bi-Specific Antibodies Therapy Revenue by Application (2017-2028)

7.3 Europe Bi-Specific Antibodies Therapy Market Size by Country

7.3.1 Europe Bi-Specific Antibodies Therapy Revenue by Country (2017-2028)

7.3.2 Germany Bi-Specific Antibodies Therapy Market Size and Forecast (2017-2028)

7.3.3 France Bi-Specific Antibodies Therapy Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Bi-Specific Antibodies Therapy Market Size and Forecast (2017-2028)

7.3.5 Russia Bi-Specific Antibodies Therapy Market Size and Forecast (2017-2028)

7.3.6 Italy Bi-Specific Antibodies Therapy Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Bi-Specific Antibodies Therapy Revenue by Type (2017-2028)

8.2 Asia-Pacific Bi-Specific Antibodies Therapy Revenue by Application (2017-2028)

8.3 Asia-Pacific Bi-Specific Antibodies Therapy Market Size by Region

8.3.1 Asia-Pacific Bi-Specific Antibodies Therapy Revenue by Region (2017-2028)

8.3.2 China Bi-Specific Antibodies Therapy Market Size and Forecast (2017-2028)

8.3.3 Japan Bi-Specific Antibodies Therapy Market Size and Forecast (2017-2028)

8.3.4 South Korea Bi-Specific Antibodies Therapy Market Size and Forecast (2017-2028)

8.3.5 India Bi-Specific Antibodies Therapy Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Bi-Specific Antibodies Therapy Market Size and Forecast (2017-2028)

8.3.7 Australia Bi-Specific Antibodies Therapy Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9.1 South America Bi-Specific Antibodies Therapy Revenue by Type (2017-2028)

9.2 South America Bi-Specific Antibodies Therapy Revenue by Application (2017-2028)

9.3 South America Bi-Specific Antibodies Therapy Market Size by Country

9.3.1 South America Bi-Specific Antibodies Therapy Revenue by Country (2017-2028)

9.3.2 Brazil Bi-Specific Antibodies Therapy Market Size and Forecast (2017-2028)

9.3.3 Argentina Bi-Specific Antibodies Therapy Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Bi-Specific Antibodies Therapy Revenue by Type (2017-2028)

10.2 Middle East & Africa Bi-Specific Antibodies Therapy Revenue by Application (2017-2028)

10.3 Middle East & Africa Bi-Specific Antibodies Therapy Market Size by Country

10.3.1 Middle East & Africa Bi-Specific Antibodies Therapy Revenue by Country (2017-2028)

10.3.2 Turkey Bi-Specific Antibodies Therapy Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Bi-Specific Antibodies Therapy Market Size and Forecast (2017-2028)

10.3.4 UAE Bi-Specific Antibodies Therapy Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Bi-Specific Antibodies Therapy Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Bi-Specific Antibodies Therapy Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Bi-Specific Antibodies Therapy Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Bi-Specific Antibodies Therapy Revenue (USD Million) by Region (2017-2022)

Table 5. Global Bi-Specific Antibodies Therapy Revenue Market Share by Region (2023-2028)

Table 6. Roche Corporate Information, Head Office, and Major Competitors

Table 7. Roche Major Business

Table 8. Roche Bi-Specific Antibodies Therapy Product and Solutions

Table 9. Roche Bi-Specific Antibodies Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Amgen Corporate Information, Head Office, and Major Competitors

Table 11. Amgen Major Business

Table 12. Amgen Bi-Specific Antibodies Therapy Product and Solutions

Table 13. Amgen Bi-Specific Antibodies Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. Sanofi Corporate Information, Head Office, and Major Competitors

Table 15. Sanofi Major Business

Table 16. Sanofi Bi-Specific Antibodies Therapy Product and Solutions

Table 17. Sanofi Bi-Specific Antibodies Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Pfizer Corporate Information, Head Office, and Major Competitors

Table 19. Pfizer Major Business

Table 20. Pfizer Bi-Specific Antibodies Therapy Product and Solutions

Table 21. Pfizer Bi-Specific Antibodies Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. Johnson & Johnson Corporate Information, Head Office, and Major Competitors

Table 23. Johnson & Johnson Major Business

Table 24. Johnson & Johnson Bi-Specific Antibodies Therapy Product and Solutions

Table 25. Johnson & Johnson Bi-Specific Antibodies Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. AstraZeneca Corporate Information, Head Office, and Major Competitors

Table 27. AstraZeneca Major Business

Table 28. AstraZeneca Bi-Specific Antibodies Therapy Product and Solutions

Table 29. AstraZeneca Bi-Specific Antibodies Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. AbbVie Corporate Information, Head Office, and Major Competitors

Table 31. AbbVie Major Business

Table 32. AbbVie Bi-Specific Antibodies Therapy Product and Solutions

Table 33. AbbVie Bi-Specific Antibodies Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 34. Lindis Biotech Corporate Information, Head Office, and Major Competitors

Table 35. Lindis Biotech Major Business

Table 36. Lindis Biotech Bi-Specific Antibodies Therapy Product and Solutions

Table 37. Lindis Biotech Bi-Specific Antibodies Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 38. MacroGenics, Inc Corporate Information, Head Office, and Major Competitors

Table 39. MacroGenics, Inc Major Business

Table 40. MacroGenics, Inc Bi-Specific Antibodies Therapy Product and Solutions

Table 41. MacroGenics, Inc Bi-Specific Antibodies Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 42. Genmab Corporate Information, Head Office, and Major Competitors

Table 43. Genmab Major Business

Table 44. Genmab Bi-Specific Antibodies Therapy Product and Solutions

Table 45. Genmab Bi-Specific Antibodies Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 46. Alphamab Co. Ltd Corporate Information, Head Office, and Major Competitors

Table 47. Alphamab Co. Ltd Major Business

Table 48. Alphamab Co. Ltd Bi-Specific Antibodies Therapy Product and Solutions

Table 49. Alphamab Co. Ltd Bi-Specific Antibodies Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 50. Akeso, Inc. Corporate Information, Head Office, and Major Competitors

Table 51. Akeso, Inc. Major Business

Table 52. Akeso, Inc. Bi-Specific Antibodies Therapy Product and Solutions

Table 53. Akeso, Inc. Bi-Specific Antibodies Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 54. Global Bi-Specific Antibodies Therapy Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 55. Global Bi-Specific Antibodies Therapy Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 56. Breakdown of Bi-Specific Antibodies Therapy by Company Type (Tier 1, Tier 2 and Tier 3)

Table 57. Bi-Specific Antibodies Therapy Players Head Office, Products and Services Provided

Table 58. Bi-Specific Antibodies Therapy Mergers & Acquisitions in the Past Five Years

Table 59. Bi-Specific Antibodies Therapy New Entrants and Expansion Plans

Table 60. Global Bi-Specific Antibodies Therapy Revenue (USD Million) by Type (2017-2022)

Table 61. Global Bi-Specific Antibodies Therapy Revenue Share by Type (2017-2022)

Table 62. Global Bi-Specific Antibodies Therapy Revenue Forecast by Type (2023-2028)

Table 63. Global Bi-Specific Antibodies Therapy Revenue by Application (2017-2022)

Table 64. Global Bi-Specific Antibodies Therapy Revenue Forecast by Application (2023-2028)

Table 65. North America Bi-Specific Antibodies Therapy Revenue by Type (2017-2022) & (USD Million)

Table 66. North America Bi-Specific Antibodies Therapy Revenue by Type (2023-2028) & (USD Million)

Table 67. North America Bi-Specific Antibodies Therapy Revenue by Application (2017-2022) & (USD Million)

Table 68. North America Bi-Specific Antibodies Therapy Revenue by Application (2023-2028) & (USD Million)

Table 69. North America Bi-Specific Antibodies Therapy Revenue by Country (2017-2022) & (USD Million)

Table 70. North America Bi-Specific Antibodies Therapy Revenue by Country (2023-2028) & (USD Million)

Table 71. Europe Bi-Specific Antibodies Therapy Revenue by Type (2017-2022) & (USD Million)

Table 72. Europe Bi-Specific Antibodies Therapy Revenue by Type (2023-2028) & (USD Million)

Table 73. Europe Bi-Specific Antibodies Therapy Revenue by Application (2017-2022) & (USD Million)

Table 74. Europe Bi-Specific Antibodies Therapy Revenue by Application (2023-2028) & (USD Million)

Table 75. Europe Bi-Specific Antibodies Therapy Revenue by Country (2017-2022) & (USD Million)

Table 76. Europe Bi-Specific Antibodies Therapy Revenue by Country (2023-2028) & (USD Million)

Table 77. Asia-Pacific Bi-Specific Antibodies Therapy Revenue by Type (2017-2022) & (USD Million)

Table 78. Asia-Pacific Bi-Specific Antibodies Therapy Revenue by Type (2023-2028) & (USD Million)

Table 79. Asia-Pacific Bi-Specific Antibodies Therapy Revenue by Application (2017-2022) & (USD Million)

Table 80. Asia-Pacific Bi-Specific Antibodies Therapy Revenue by Application (2023-2028) & (USD Million)

Table 81. Asia-Pacific Bi-Specific Antibodies Therapy Revenue by Region (2017-2022) & (USD Million)

Table 82. Asia-Pacific Bi-Specific Antibodies Therapy Revenue by Region (2023-2028) & (USD Million)

Table 83. South America Bi-Specific Antibodies Therapy Revenue by Type (2017-2022) & (USD Million)

Table 84. South America Bi-Specific Antibodies Therapy Revenue by Type (2023-2028) & (USD Million)

Table 85. South America Bi-Specific Antibodies Therapy Revenue by Application (2017-2022) & (USD Million)

Table 86. South America Bi-Specific Antibodies Therapy Revenue by Application (2023-2028) & (USD Million)

Table 87. South America Bi-Specific Antibodies Therapy Revenue by Country (2017-2022) & (USD Million)

Table 88. South America Bi-Specific Antibodies Therapy Revenue by Country (2023-2028) & (USD Million)

Table 89. Middle East & Africa Bi-Specific Antibodies Therapy Revenue by Type (2017-2022) & (USD Million)

Table 90. Middle East & Africa Bi-Specific Antibodies Therapy Revenue by Type (2023-2028) & (USD Million)

Table 91. Middle East & Africa Bi-Specific Antibodies Therapy Revenue by Application (2017-2022) & (USD Million)

Table 92. Middle East & Africa Bi-Specific Antibodies Therapy Revenue by Application (2023-2028) & (USD Million)

Table 93. Middle East & Africa Bi-Specific Antibodies Therapy Revenue by Country (2017-2022) & (USD Million)

Table 94. Middle East & Africa Bi-Specific Antibodies Therapy Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. Bi-Specific Antibodies Therapy Picture

Figure 2. Global Bi-Specific Antibodies Therapy Revenue Market Share by Type in 2021

Figure 3. Fragment-Based Antibodies

Figure 4. IgG-Based Antibodies

Figure 5. Bi-Specific Antibodies Therapy Revenue Market Share by Application in 2021

Figure 6. Cancer Picture

Figure 7. Haemophilia Picture

Figure 8. Other Non-Cancer Diseases Picture

Figure 9. Global Bi-Specific Antibodies Therapy Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 10. Global Bi-Specific Antibodies Therapy Revenue and Forecast (2017-2028) & (USD Million)

Figure 11. Global Bi-Specific Antibodies Therapy Revenue Market Share by Region (2017-2028)

Figure 12. Global Bi-Specific Antibodies Therapy Revenue Market Share by Region in 2021

Figure 13. North America Bi-Specific Antibodies Therapy Revenue (USD Million) and Growth Rate (2017-2028)

Figure 14. Europe Bi-Specific Antibodies Therapy Revenue (USD Million) and Growth Rate (2017-2028)

Figure 15. Asia-Pacific Bi-Specific Antibodies Therapy Revenue (USD Million) and Growth Rate (2017-2028)

Figure 16. South America Bi-Specific Antibodies Therapy Revenue (USD Million) and Growth Rate (2017-2028)

Figure 17. Middle East and Africa Bi-Specific Antibodies Therapy Revenue (USD Million) and Growth Rate (2017-2028)

Figure 18. Bi-Specific Antibodies Therapy Market Drivers

Figure 19. Bi-Specific Antibodies Therapy Market Restraints

Figure 20. Bi-Specific Antibodies Therapy Market Trends

Figure 21. Roche Recent Developments and Future Plans

Figure 22. Amgen Recent Developments and Future Plans

Figure 23. Sanofi Recent Developments and Future Plans

Figure 24. Pfizer Recent Developments and Future Plans

Figure 25. Johnson & Johnson Recent Developments and Future Plans

Figure 26. AstraZeneca Recent Developments and Future Plans

Figure 27. AbbVie Recent Developments and Future Plans

Figure 28. Lindis Biotech Recent Developments and Future Plans

Figure 29. MacroGenics, Inc Recent Developments and Future Plans

Figure 30. Genmab Recent Developments and Future Plans

Figure 31. Alphamab Co. Ltd Recent Developments and Future Plans

Figure 32. Akeso, Inc. Recent Developments and Future Plans

Figure 33. Global Bi-Specific Antibodies Therapy Revenue Share by Players in 2021

Figure 34. Bi-Specific Antibodies Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 35. Global Top 3 Players Bi-Specific Antibodies Therapy Revenue Market Share in 2021

Figure 36. Global Top 10 Players Bi-Specific Antibodies Therapy Revenue Market Share in 2021

Figure 37. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 38. Global Bi-Specific Antibodies Therapy Revenue Share by Type in 2021

Figure 39. Global Bi-Specific Antibodies Therapy Market Share Forecast by Type (2023-2028)

Figure 40. Global Bi-Specific Antibodies Therapy Revenue Share by Application in 2021

Figure 41. Global Bi-Specific Antibodies Therapy Market Share Forecast by Application (2023-2028)

Figure 42. North America Bi-Specific Antibodies Therapy Sales Market Share by Type (2017-2028)

Figure 43. North America Bi-Specific Antibodies Therapy Sales Market Share by Application (2017-2028)

Figure 44. North America Bi-Specific Antibodies Therapy Revenue Market Share by Country (2017-2028)

Figure 45. United States Bi-Specific Antibodies Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 46. Canada Bi-Specific Antibodies Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 47. Mexico Bi-Specific Antibodies Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 48. Europe Bi-Specific Antibodies Therapy Sales Market Share by Type (2017-2028)

Figure 49. Europe Bi-Specific Antibodies Therapy Sales Market Share by Application (2017-2028)

Figure 50. Europe Bi-Specific Antibodies Therapy Revenue Market Share by Country (2017-2028)

Figure 51. Germany Bi-Specific Antibodies Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 52. France Bi-Specific Antibodies Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 53. United Kingdom Bi-Specific Antibodies Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 54. Russia Bi-Specific Antibodies Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 55. Italy Bi-Specific Antibodies Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 56. Asia-Pacific Bi-Specific Antibodies Therapy Sales Market Share by Type (2017-2028)

Figure 57. Asia-Pacific Bi-Specific Antibodies Therapy Sales Market Share by Application (2017-2028)

Figure 58. Asia-Pacific Bi-Specific Antibodies Therapy Revenue Market Share by Region (2017-2028)

Figure 59. China Bi-Specific Antibodies Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 60. Japan Bi-Specific Antibodies Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 61. South Korea Bi-Specific Antibodies Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 62. India Bi-Specific Antibodies Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 63. Southeast Asia Bi-Specific Antibodies Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 64. Australia Bi-Specific Antibodies Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 65. South America Bi-Specific Antibodies Therapy Sales Market Share by Type (2017-2028)

Figure 66. South America Bi-Specific Antibodies Therapy Sales Market Share by Application (2017-2028)

Figure 67. South America Bi-Specific Antibodies Therapy Revenue Market Share by Country (2017-2028)

Figure 68. Brazil Bi-Specific Antibodies Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 69. Argentina Bi-Specific Antibodies Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 70. Middle East and Africa Bi-Specific Antibodies Therapy Sales Market Share by Type (2017-2028)

Figure 71. Middle East and Africa Bi-Specific Antibodies Therapy Sales Market Share by Application (2017-2028)

Figure 72. Middle East and Africa Bi-Specific Antibodies Therapy Revenue Market Share by Country (2017-2028)

Figure 73. Turkey Bi-Specific Antibodies Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 74. Saudi Arabia Bi-Specific Antibodies Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 75. UAE Bi-Specific Antibodies Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 76. Methodology

Figure 77. Research Process and Data Source